Bacterial Composition Linked to Breast Cancer
By LabMedica International staff writers Posted on 19 Oct 2017 |

Image: The Quantiflour dsDNA system for sensitive quantitation of double-stranded DNA in solution (Photo courtesy of Promega).
Breast cancer is the second most common cancer in women (after skin cancer) in the USA, where one in eight women will develop the disease in their lifetimes. Bacteria that live in the body is known as the microbiome, and influence many diseases.
Most studies have been done on the "gut" microbiome, or bacteria in the digestive tract. Scientists have long suspected that a "microbiome" exists within breast tissue and plays a role in breast cancer, but it has not yet been characterized. Recently they have uncovered differences in the bacterial composition of breast tissue of healthy women versus women with breast cancer.
Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the tissues of 78 patients who underwent mastectomy for invasive carcinoma or elective cosmetic breast surgery. In addition, they examined oral rinse and urine to determine the bacterial composition of these distant sites in the body. Breast cancer patients eligible for inclusion for this study were over 18 years of age, female, had tumors greater than or equal to 2 cm in size, and were undergoing mastectomy.
The team extracted total DNA was from the breast tissue, environmental controls, urine, and oral rinse pellets using PowerMag Microbiome RNA/DNA Isolation Kit. For breast samples, the polymerase chain reaction (PCR) product showed nonspecific bands on a 1% agarose gel. A second round of Ampure XP cleanup was performed and resulting libraries were quantified with Quantiflour dsDNA system. Libraries were validated on a Bioanalyzer DNA 1000 chip to verify size and sequenced.
The scientists found that cancer patient breast tissue microbiomes clustered significantly differently from non-cancer patients, largely driven by decreased relative abundance of Methylobacterium in cancer patients (median 0.10 versus 0.24). There were no significant differences in oral rinse samples. Differences in urinary microbiomes were largely explained by menopausal status, with peri/postmenopausal women showing decreased levels of Lactobacillus. Independent of menopausal status, however, cancer patients had increased levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae.
Charis Eng, MD, PhD, the co-senior author of the study, said, “To my knowledge, this is the first study to examine both breast tissue and distant sites of the body for bacterial differences in breast cancer. Our hope is to find a biomarker that would help us diagnose breast cancer quickly and easily. In our wildest dreams, we hope we can use microbiomics right before breast cancer forms and then prevent cancer with probiotics or antibiotics.” The study was published on October 5, 2017, in the journal Oncotarget.
Related Links:
Cleveland Clinic
Most studies have been done on the "gut" microbiome, or bacteria in the digestive tract. Scientists have long suspected that a "microbiome" exists within breast tissue and plays a role in breast cancer, but it has not yet been characterized. Recently they have uncovered differences in the bacterial composition of breast tissue of healthy women versus women with breast cancer.
Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the tissues of 78 patients who underwent mastectomy for invasive carcinoma or elective cosmetic breast surgery. In addition, they examined oral rinse and urine to determine the bacterial composition of these distant sites in the body. Breast cancer patients eligible for inclusion for this study were over 18 years of age, female, had tumors greater than or equal to 2 cm in size, and were undergoing mastectomy.
The team extracted total DNA was from the breast tissue, environmental controls, urine, and oral rinse pellets using PowerMag Microbiome RNA/DNA Isolation Kit. For breast samples, the polymerase chain reaction (PCR) product showed nonspecific bands on a 1% agarose gel. A second round of Ampure XP cleanup was performed and resulting libraries were quantified with Quantiflour dsDNA system. Libraries were validated on a Bioanalyzer DNA 1000 chip to verify size and sequenced.
The scientists found that cancer patient breast tissue microbiomes clustered significantly differently from non-cancer patients, largely driven by decreased relative abundance of Methylobacterium in cancer patients (median 0.10 versus 0.24). There were no significant differences in oral rinse samples. Differences in urinary microbiomes were largely explained by menopausal status, with peri/postmenopausal women showing decreased levels of Lactobacillus. Independent of menopausal status, however, cancer patients had increased levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae.
Charis Eng, MD, PhD, the co-senior author of the study, said, “To my knowledge, this is the first study to examine both breast tissue and distant sites of the body for bacterial differences in breast cancer. Our hope is to find a biomarker that would help us diagnose breast cancer quickly and easily. In our wildest dreams, we hope we can use microbiomics right before breast cancer forms and then prevent cancer with probiotics or antibiotics.” The study was published on October 5, 2017, in the journal Oncotarget.
Related Links:
Cleveland Clinic
Latest Molecular Diagnostics News
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
- Blood Test Shows Promise for Early Detection of Dementia
- CRISPR-Based Diagnostic Test Detects Pathogens in Blood Without Amplification
- Portable Blood-Based Device Detects Colon Cancer
- New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
- Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more